Characterisation of LDL receptor gene mutations in a North Indian cohort of children with homozygous familial hypercholesterolaemia.
Charakterystyka mutacji genów receptora LDL w kohorcie północnoindyjskiej dzieci z homozygotyczną rodzinną hipercholesterolemią.
Indian families.
LDLR gene
pathogenic variants
homozygous familial hypercholesterolaemia
Journal
Pediatric endocrinology, diabetes, and metabolism
ISSN: 2083-8441
Titre abrégé: Pediatr Endocrinol Diabetes Metab
Pays: Poland
ID NLM: 101518750
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
18
2
2021
pubmed:
19
2
2021
medline:
31
8
2021
Statut:
ppublish
Résumé
Homozygous familial hypercholesterolaemia (HoFH) carries a grave prognosis but is often underdiagnosed and undertreated. Confirmation of molecular diagnosis helps in planning effective management and determining prognosis accurately. Aim of the study: To determine the spectrum of mutations in the LDLR gene in a cohort of children with a clinical diagnosis of HoFH. Genomic DNA was extracted from peripheral blood samples of 8 patients, who were children of either sex, aged under 16 years, and diagnosed clinically with HoFH using the Simon Broome criteria. The potential variants in the LDLR gene were analysed by Sanger sequencing. Fifty variations were found in the 8 patients; 39 (78%) were single nucleotide variations while 8 (16%) and 3 (6%) were deletions and insertions, respectively. The pathogenic variants in the LDLR gene were detected in four patients; three showed duplication in exon 17 (c.2416dupG) creating an amino acid change at position 806 (p.Val806GlyfsTer11) while one had a missense variant in the exon 9 at position c.1285G>A resulting in a change in amino acid at position 429 (p.Val429Met). The variants were found in heterozygous state in the parents or siblings of probands who showed pathogenic variants. The frequency of disease-causing variants in the LDLR gene in our patients with HoFH was 50%. Further studies to characterise mutations in genes for apolipoprotein B, proprotein convertase subtilisin/kexin type 9, or LDL adaptor protein are suggested in all children with a clinical diagnosis of HoFH.
Identifiants
pubmed: 33599434
pii: 43132
doi: 10.5114/pedm.2020.103056
pmc: PMC10227482
pii:
doi:
Substances chimiques
LDLR protein, human
0
Receptors, LDL
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
32-36Références
Arch Med Res. 2020 Feb;51(2):153-159
pubmed: 32113782
J Clin Med. 2020 Jan 14;9(1):
pubmed: 31947532
Atherosclerosis. 2002 Dec;165(2):335-42
pubmed: 12417285
Glob Heart. 2020 Feb 28;15(1):19
pubmed: 32489792
Ann Hum Genet. 2012 Sep;76(5):387-401
pubmed: 22881376
BMJ. 2001 Apr 28;322(7293):1062
pubmed: 11349661
Diabetol Int. 2019 Nov 12;11(2):142-149
pubmed: 32206484
Turk Pediatri Ars. 2018 Dec 1;53(4):267-268
pubmed: 30872932
J Clin Invest. 1989 Sep;84(3):954-61
pubmed: 2569482
Eur J Hum Genet. 2015 Mar;23(3):381-7
pubmed: 24916650
Atherosclerosis. 2016 Dec;255:31-36
pubmed: 27816806
Indian J Pediatr. 2018 May;85(5):339-343
pubmed: 29450819
J Clin Lipidol. 2018 Jan - Feb;12(1):25-32
pubmed: 29208363
Atherosclerosis. 2013 Apr;227(2):342-8
pubmed: 23375686
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Genet Test Mol Biomarkers. 2011 Sep;15(9):601-6
pubmed: 21457052
Mol Diagn Ther. 2019 Aug;23(4):547-553
pubmed: 31172370
Atherosclerosis. 2018 Oct;277:483-492
pubmed: 30270089
Curr Atheroscler Rep. 2015;17(2):482
pubmed: 25612857
Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):1594-9
pubmed: 26811443